Amended Current Report Filing (8-k/a)
October 07 2016 - 4:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 1, 2016
SYNDAX
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37708
|
|
32-0162505
|
(state or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
400 Totten Pond Road, Suite 110
Waltham, Massachusetts
|
|
02451
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (781) 419-1400
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Explanatory Note
On July 6, 2016, Syndax Pharmaceuticals, Inc. (the
Company
) filed a Current Report on Form 8-K (the
Original
Report
) to report that the Company entered into a license agreement (the
Agreement
) with UCB Biopharma Sprl. This Current Report on Form 8-K/A amends the Original Report solely to file the Agreement as an
exhibit hereto. The other disclosures made in the Original Report remain unchanged.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
10.1
|
|
License Agreement, by and between the Company and UCB Biopharma Sprl, dated July 1, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
SYNDAX PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Briggs W. Morrison, M.D.
|
|
|
Briggs W. Morrison, M.D.
|
|
|
Chief Executive Officer
|
Dated: October 7, 2016
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
10.1
|
|
License Agreement, by and between the Company and UCB Biopharma Sprl, dated July 1, 2016.
|
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Apr 2023 to Apr 2024